Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
Conditions
- Triple Negative Breast Cancer
Interventions
- DRUG: GX-I7
- DRUG: Pembrolizumab(KEYTRUDA®)
- DRUG: Cyclophosphamide
Sponsor
Genexine, Inc.
Collaborators